Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 6Melanoma 3Neoplasm Metastasis 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Ovarian Neoplasms 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Neuroendocrine Tumors 1Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1HIV Infections 1Fallopian Tube Neoplasms 1Congenital Abnormalities 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 26Nivolumab 10Docetaxel 8avelumab 7atezolizumab 7Gemcitabine 7Carboplatin 6Trastuzumab 5Ipilimumab 5Radiosurgery 4Psychiatric Rehabilitation 4Immunoglobulin G 4Early Intervention, Educational 4Cyclophosphamide 4fludarabine 3durvalumab 3cemiplimab 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Disulfides 3Counseling 3Cisplatin 3Blood Specimen Collection 3Biopsy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3zimberelimab 2utomilumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × CTLA-4 Antigen × Thoracic × Clear all
NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡